Co­di­ak Bio­sciences out­lines a new fo­cus for its ex­o­some plat­form in $86M IPO fil­ing

Ven­ture rais­es from mar­quee in­vestors? Check. Col­lab­o­ra­tion deal? Check. Clin­i­cal tri­al time­line? Check. For its next step, Co­di­ak Bio­sciences is head­ed for an IPO. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.